Učitavanje...
ACTR-24. THE ESTIMATED LONG-TERM SURVIVAL BENEFIT OF ADDING TTFIELDS TO THE STANDARD OF CARE FOR GLIOBLASTOMA PATIENTS
BACKGROUND: Glioblastoma (GBM) is the most aggressive form of primary brain cancer. The EF-14 trial for GBM patients reported a 5-year survival rate of 12.8%, the first report from a large randomized controlled trial of 5-year survival greater than 10%. The increased survival compared to previous st...
Spremljeno u:
| Izdano u: | Neuro Oncol |
|---|---|
| Glavni autori: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Oxford University Press
2017
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5692846/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.019 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|